Maria Vlachou

Dr. Maria Vlachou

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
MVMaria Vlachou
Maria Vlachou
VKVasileios Kamperidis
Vasileios Kamperidis
George GiannakoulasGeorge Giannakoulas
George Giannakoulas
Theodoros D. KaramitsosTheodoros D. Karamitsos
Theodoros D. Karamitsos
EVEfthymia Vlachaki
Efthymia Vlachaki
HKHaralambos Karvounis
Haralambos Karvounis
Beta-thalassaemia is a genetic disease with different clinical aspects, which can lead to heart failure with a multifactorial mechanism. Over the last years, growing interest has been reported for biomarkers which may help in the diagnosis, staging and prognosis of heart disease at an early stage, in patients with beta-thalassaemia. This review will highlight the current clinical value of cardiac biomarkers in beta-thalassaemia patients and the ongoing research for a possible expanded future use.

1 November 2021 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
VKVasileios Kamperidis
Vasileios Kamperidis
MVMaria Vlachou
Maria Vlachou
ZPZoi Pappa
Zoi Pappa
DPDespoina Pantelidou
Despoina Pantelidou
TKTheodoros Karamitsos
Theodoros Karamitsos
HKHaralambos Karvounis
Haralambos Karvounis
The current study evaluated the association of echocardiography, cardiac magnetic resonance (CMR) and ferritin data with the 10-years survival in thalassaemia patients. Demographics, ferritin, echocardiography and CMR parameters of stable consecutive thalassaemia patients were prospectively collected. In total, 75 patients (mean age 37±11 years, 45% male) with thalassaemia were included and dichotomized based on their survival status after a median follow-up period of 10.3 [9.6-10.9] years. Older age (HR: 1.071, p=0.001), ferritin ≥2000ng/ml (HR: 4.682, p=0.007), and ≥1700ng/ml (HR: 7.817, p=0.002), elevated LV end-diastolic pressure (HR: 1.019, p=0.044), TR Vmax >2.8m/s (HR: 6.845, p=0.005), CMR T2* ≤20msec (HR: 3.602, p=0.043) and ≤34msec (HR: 5.854, p=0.026) were associated with increased all-cause mortality (primary end-point). A baseline model including age was created and it became more predictive of worse survival by adding TR Vmax >2.8m/s than elevated LV end-diastolic pressure (C index 0.767 vs. 0.760 respectively) or ferritin ≥1700ng/ml than ≥2000ng/ml (C index 0.890 vs. 0.807 respectively) or CMR T2*≤34msec than ≤20msec (C index 0.845 vs. 0.839 respectively). Parameters associated with the combined end-point of cardiac mortality/cardiac hospitalization (secondary end-point) after adjusting for the age were: ferritin ≥1700ng/ml (HR 3.770, p=0.014), ratio E/A wave >2 (HR 3.565, p=0.04), TR Vmax >2.8m/s (HR 4.541, p=0.049), CMR T2* ≤20ms (HR 9.462, p=0.001) and CMR T2* ≤34ms (HR 11.735, p=0.002). The model including age and T2* ≤34ms than T2* ≤20ms was more predictive of the secondary end-point (C-index 0.844 vs 0.838, respectively). In thalassaemia patients, TR Vmax >2.8m/s, ferritin ≥2000ng/ml and CMR T2* ≤20ms were associated with worse long term survival. In the current era of advanced chelation therapy, aiming for ferritin ≤1700ng/ml and CMR T2* ≥34ms may improve their prognosis.

22 December 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
MVMaria Vlachou
Maria Vlachou
VKVasileios Kamperidis
Vasileios Kamperidis
EVEFTHYMIA VLACHAKI
EFTHYMIA VLACHAKI
GTGeorgios Tziatzios
Georgios Tziatzios
DPDespina Pantelidou
Despina Pantelidou
HKHaralambos Karvounis
Haralambos Karvounis
Patients with beta-thalassemia major (β-ΤΜ) may develop cardiac arrhythmias through a multifactorial mechanism. The current study evaluated the association of cardiac structure and function on echocardiography with atrial ectopic burden on 24-hour tape recording in β-ΤΜ patients. This prospective study included consecutive β-ΤΜ patients. Demographic, laboratory, echocardiographic, cardiac magnetic resonance (CMR) T2* and 24-hour tape recording data were prospectively collected. The patients were classified according to the median value of premature atrial contractions (PACs) on 24-hour tape. In total, 50 β-TM patients (37.6 ± 9.1 years old, 50% male) were divided in 2 groups; PACs ≤ 24/day and > 24/day. Patients with PACs > 24/day were treated with blood transfusion for a longer period of time (39.0 ± 8.6 vs. 32.0 ± 8.9 years, p < 0.007), compared to their counterparts. Older age (OR: 1.121, 95% CI: 1.032–1.217, p = 0.007), longer duration of blood transfusion (OR:1.101, 95% CI:1.019–1.188, p = 0.014), larger LV end-diastolic diameter (OR: 4.522, 95% CI:1.009–20.280, p = 0.049), higher values of LA peak systolic strain (OR: 0.869, 95% CI: 0.783–0.964, p = 0.008), higher MV E/E′ average (OR: 1.407, 95% CI: 1.028–1.926, p = 0.033) and higher right ventricular systolic pressure (OR: 1.147, 95% CI: 1.039–1.266, p = 0.006) were univariably associated with PACs > 24/day. LA peak systolic strain remained significantly associated with PACs > 24/day after adjusting for the duration of blood transfusions or for CMR T2*. The multivariable model including blood transfusion duration and LA peak systolic strain was the most closely associated with PACs > 24/day. Receiver operating characteristic curve analysis identified a left atrial peak systolic strain of 31.5%, as the best cut-off value (83% sensitivity, 68% specificity) for prediction of PACs > 24/day. In β-TM patients, LA peak systolic strain was associated with the atrial arrhythmia burden independently to the duration of blood transfusions and CMR T2*.